Stay updated on Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.

Latest updates to the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded revision v3.6.4 to the history and removed v3.6.3, reflecting a small update to the page’s version history.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedA newer revision entry (v3.6.3) was added to the record history and an older revision (v3.6.0) was removed, updating the history to reflect the latest version.SummaryDifference0.1%

- Check56 days agoChange DetectedThe study record shows recruitment has closed to new participants and the record has been revised to version v3.6.0, replacing the prior v3.5.5 label.SummaryDifference0.4%

- Check63 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the study history page.SummaryDifference0.1%

- Check85 days agoChange DetectedThe bottom revision stamp updates from v3.5.3 to v3.5.4, reflecting a new revision of the record history. This indicates the study record has been updated.SummaryDifference0.1%

- Check107 days agoChange DetectedUpdated the ClinicalTrials.gov interface/revision label from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

Stay in the know with updates to Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.